Advances in Genetics
- 1st Edition, Volume 108 - November 16, 2021
- Editor: Dhavendra Kumar
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 7 8 5 - 4
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 7 8 6 - 1
Advances in Genetics, Volume 108 provides the latest information on genetics, presenting new medical breakthroughs that are occurring as a result of advances in our knowledge… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteAdvances in Genetics, Volume 108 provides the latest information on genetics, presenting new medical breakthroughs that are occurring as a result of advances in our knowledge of the topic. The book continually publishes important reviews of the broadest interest to geneticists and their colleagues in affiliated disciplines, with this new release including chapters on Clinical applications of cancer genetics and genomics, Epigenetic mutations in childhood tumors- the paradigm of Wilms tumor, Preventive population genomics-the model of BRCA related cancers, Recent advances of PARP inhibitors in medical oncology, Role of single cell and liquid biopsy in cancer research and clinical applications.
Other chapters cover Recent advances and clinical utility of prostate cancer genomics, Recent advances in lung cancer genomics- applications in targeted therapy, and more.
- Critically analyzes future directions for the study of clinical genetics
- Written and edited by recognized leaders in the field
- Presents new medical breakthroughs that are occurring as a result of advances in our knowledge of genetics
Molecular geneticists, clinical geneticists, neurologists, neuroscientists, molecular biologists, and biochemists
- Cover
- Title page
- Table of Contents
- Copyright
- Contributors
- Preface
- References
- Chapter One: Preventive population genomics: The model of BRCA related cancers
- Abstract
- 1: Preventive population genomics: The model of BRCA related cancers
- 2: The traditional clinical genetic testing approach
- 3: Population genomics: The Jewish BRCA model
- 4: Population genomics: BRCA testing in the wider general population
- 5: Pre-test genetic education and counseling: Yes or No?
- 6: Population genomics: Beyond BRCA
- 7: Conclusions
- References
- Chapter Two: PARP inhibitors in hereditary breast and ovarian cancer and other cancers: A review
- Abstract
- 1: Introduction
- 2: Molecular concepts with HBOC and PARPi
- 3: DNA repair systems
- 4: PARP inhibitors
- 5: Toxicity
- 6: Management of toxicities
- 7: Indications of use of PARP inhibitors
- 8: Mechanisms of resistance
- 9: Overcoming resistance: PARPi and combination with other agents
- 10: Functional cure in advanced disease?
- 11: Future developments
- References
- Chapter Three: Novel omics technology driving translational research in precision oncology
- Abstract
- 1: Introduction
- 2: Challenges in cancer
- 3: Novel genomic technologies and their application in precision oncology
- 4: Conclusion: Integration, challenges and future directions
- References
- Chapter Four: Genetics of prostate cancer and its utility in treatment and screening
- Abstract
- 1: Introduction
- 2: Germline mutations and prostate cancer
- 3: Common variants contributing to prostate cancer risk
- 4: Current management of men with increased risk of prostate cancer development
- 5: Current guidance on germline and somatic testing in prostate cancer
- 6: Personalized treatment for prostate cancer
- 7: Conclusions and future directions
- References
- Chapter Five: Recent advances in lung cancer genomics: Application in targeted therapy
- Abstract
- 1: Introduction
- 2: Oncogene addiction
- 3: One disease model to molecular classification
- 4: Ethnic variations in genomic profile
- 5: Intra-tumoral heterogeneity
- 6: Clinical implications of genomic understanding of lung cancer
- 7: Biomarker testing in lung cancer
- 8: Methods of biomarker testing
- 9: Therapeutic landscape of genomics directed treatments in NSCLC
- 10: Immunotherapy and genomics
- 11: Small cell lung cancer
- 12: Conclusion
- References
- Chapter Six: Nutrigenetics and nutrigenomics—A personalized approach to nutrition
- Abstract
- 1: Introduction
- 2: Obesity—A thrifty response
- 3: Nutrigenetics: Genetic variants-targets of personalized approach
- 4: Nutrigenomics: Diet modulates expression of the genome
- 5: PPARγ at the crossroads of nutrigenetics and nutrigenomics
- 6: PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9: A target for nutraceutical intervention
- 7: Epigenetics: Genes are not destiny
- 8: Diet-gut microbiota interactions
- 9: Eating behaviors
- 10: Resveratrol: A multifaceted nutraceutical
- 11: Conclusion
- References
- Chapter Seven: Next-generation microbial drugs developed from microbiome's natural products
- Abstract
- 1: Introduction
- 2: Microbiome, metagenome, and metabolites
- 3: Host–microbes' interactions and metabolic trade-off
- 4: Metabolite's bioactivity and associated diseases
- 5: Microbiomes metabolites as therapeutic leads
- 6: Characterization of microbiomes SMs
- 7: Microbiome habitats
- 8: Xenobiotics
- 9: Challenges and future perspectives
- References
- No. of pages: 396
- Language: English
- Edition: 1
- Volume: 108
- Published: November 16, 2021
- Imprint: Academic Press
- Hardback ISBN: 9780128237854
- eBook ISBN: 9780128237861
DK
Dhavendra Kumar
Professor Kumar has considerable previous experience in writing and editing books and journals related to genetics and genomics. His books include Genomics and Clinical Medicine and Genomics and Health in the Developing World. He founded and leads the new open access journal Applied and Translational Genomics, published by Elsevier. He has published 40 articles in the journals literature.
Professor Dhavendra Kumar is a Visiting Professor, Genomic Policy Unit, Faculty of Life Sciences and Education, The University of South Wales and Consultant in Clinical Genetics at the University Hospital of Wales, Institute of Medical Genetics, Cardiff University, Cardiff, United Kingdom. He is one of the Consultants for the All Wales Medical Genetics Service and the lead Clinician for Clinical Cardiovascular Genetics. After qualifying in Medicine from the King George’s Medical College, University of Lucknow, India, he completed postgraduate training in Pediatrics with an MD. Since 1980 he has pursued a career in Medical Genetics in the UK. In 1990 he became a Diplomate of the American Board of Medical Genetics. He is a Fellow of the American College of Medical Genetics (FACMG) and as well as Royal Colleges of Physicians (FRCP-London and FRCP-Ireland) and Pediatrics and Child Health (FRCPCH-UK).
In 2015, he was conferred with the higher degree of DSc by his Alma Mater, King George’s Medical University, Lucknow (UP, India) based on his life-time contributions and achievements to genetic and genomic applications in medicine and health.
Affiliations and expertise
Honorary Clinical Professor, William Harvey Research Institute, Queen Mary University of London, UKRead Advances in Genetics on ScienceDirect